A Lot of Investors Are Still Shorting Celldex Therapeutics, Inc. (CLDX)

How do you judge Wall Street’s opinion of CLDX stock? You could look at price, sure. But that doesn’t tell the whole story. Short sellers are betting against Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the most recent two-week period. Looking at the sentiment indicator for the CLDX stock we see that the short-interest ratio is at 1 while the average analyst recommendations at 2 suggests buying these shares. Between January 15 and January 31, the total number of shorted shares amounted to 2.15 million shares. That was 1.27% more than the total of 2.12 million shares in the space of prior two weeks, which means more traders or funds betting that the stock will go down. Average daily volume for Celldex Therapeutics, Inc. at the January 31st settlement jumped to 4,820,803, as compared to 1,565,027 at the January 15th report. That brought days to cover 26.17% down from the 1.354462 days to cover recorded at the prior short interest data release.

Analysts are forecasting revenue to suffer decline of -57.8 percent to $1.46M in the next fiscal quarter, while earnings are seen soaring by nearly 166.67 percent to -$0.08 per share. History has shown that shares in Celldex Therapeutics, Inc. have gone down on 18 different earnings reaction days and are predicted to add 0.04 percent when the company reports upcoming earnings. In last reported earnings results, it earned -$0.04 per share, better than the -$0.15, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $940000, worse than the $1.89M analysts expected. Earnings are estimated to increase by 31.1 percent this year, 60 percent next year and continue to increase by 0 percent annually for the next 5 years.

The stock is currently hovering around the first support level of $4.96. Below this, the next support is placed in the zone of $4.39. Till the time, the CLDX stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 48.7 on daily chart, which may remain a cause for concern. If the price breaks below $4.39 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $5.97 mark may result into a pull-back move towards $6.41 level.

On 13th of February, Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares ended higher after a volatile session. The shares accumulated 0.54 points or 10.82 percent at $5.53 with a light trade volume of 1.246 million shares. After opening the session at $4.97, the shares went as high as $5.8409 and as low as $4.83, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $1.39 billion and now has 250.51 million shares outstanding. Celldex Therapeutics, Inc. (CLDX) stock has gained 41.96 percent of market value in 21 trading days.

CLDX stock has a trailing 3-year beta of 4.45, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$1.16 a share in the trailing twelve months. The stock’s value has surged 86.29 percent year to date (YTD) against a decline of -84.31 percent in 12 month’s time. The company’s shares still trade -87.11 percent away from its 1-year high of $42.90 and 101.46 percent up from 52-week low of $2.74. The average consensus rating on the company is 2, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.

Shares of Celldex Therapeutics, Inc. (CLDX) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry CLDX operates in has an average P/E of 88.07. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 123.69 on the Price-to-Sales ratio. Compare this with the industry average P/S of 51.29. 0 percent is the gross profit margin for Celldex Therapeutics, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.

Let’s take a look at some insider activity at Celldex Therapeutics, Inc. (NASDAQ:CLDX) and see the pattern. The earliest insider trade took place on 08/24/2018. Marino James J gathered a total of 40 thousand shares of company at average share price of $0.48. The total for the purchase was set at $19.2 thousand. After this transaction, the Director account balance stood at 66 thousand shares. The stock grew 1102.08 percent since that insider purchase. On 06/15/2018, Keler Tibor, Executive VP & CSO, purchased 16.5 thousand shares at a price per share of $0.59. This added 9.74 thousand shares to the insider’s fortune and the stock saw a 877.97 percent rally in value since the news became public. This transaction left 35.37 thousand shares in the Executive VP & CSO account.

On 09/02/2016, Executive VP & CSO Keler Tibor performed a purchase transaction worth $9.96 thousand. This purchase at $3.32 each has added 3 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded 73.8 percent increase since the transaction was reported. The insider now is left with 18.87 thousand shares remaining in the account. Catlin Avery W, who performs the Sr. VP & CFO job, sold 25 thousand shares for $450 thousand. The disposal occurred on 11/23/2015 was priced at $18 per share. The share price plunged -67.94 percent since the reporting date. Catlin Avery W now left with a stake of 35.11 thousand CLDX stock worth $194.15 thousand after the insider selling.